Market conditions remain tough, which is weighing on demand for both Schrödinger's software and drug discovery services. Investors continue to punish Schrödinger's investments in drug discovery, ...
Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, ...
Schrodinger reported robust software and drug discovery revenue in the second quarter. Lilly's planned multi-billion-dollar acquisition of Morphic also provides another validation point for ...
Total Revenue (Q4 2024): $88.3 million, a 19% increase compared to Q4 2023. Software Revenue (Q4 2024): $79.7 million, a 16% increase compared to Q4 2023. Drug Discovery Revenue (Q4 2024): $8.7 ...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s ...
NEW YORK, May 29, 2025--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief ...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today will host its first annual ...
The integration of TuneLab into Schrodinger’s cloud-based LiveDesign platform will provide biotech companies with direct ...
Mr. Aklian joins Schrödinger from Certara, where he served as senior vice president, global software sales. In this role, Mr. Aklian led a global team of professionals in sales and operations and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback